Back to top

gene-editing: Archive

Zacks Equity Research

CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss

CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.

VRTXNegative Net Change UTHRNegative Net Change LGNDNegative Net Change CRSPNegative Net Change